Press Release
« Back
Celldex Therapeutics Announces Varlilumab (CDX-1127) Phase 1 Clinical Data to be Presented at ASCO Annual Meeting 2014
May 14, 2014
-
(# 3024) Data from the hematologic malignancy dose-escalation arm will be presented by
Stephen M. Ansell , MD, PhD, Professor of Medicine,Mayo Clinic , in a poster entitled "Phase 1 Evaluation of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies" on Monday, June 2 from 1:15 to 4:15 p.m. CDT.
-
(# 3027) Data from the solid tumor expansion cohorts in metastatic melanoma and renal cell carcinoma will be presented by
Jeffrey R. Infante , MD, Director, Drug Development Program,Sarah Cannon Research Institute , in a poster entitled "Immunologic Activity of an Activating Anti-CD27 Antibody (CDX-1127) in Patients with Solid Tumors" on Monday, June 2 from1:15 to 4:15 p.m. CDT .
Data contained in the published abstracts was current as of the submission deadline of
About
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
CONTACT: Company Contact:Source:Sarah Cavanaugh Vice President of Investor Relations& Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 scavanaugh@celldex.com Media Inquiries:Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com
News Provided by Acquire Media